Published in final edited form as:

Tetrahedron Lett. 2010 March 3; 51(9): 1322. doi:10.1016/j.tetlet.2009.12.139.

Organocatalyzed synthesis of 2-amino-8-oxo-5,6,7,8-tetrahydro-4*H*-chromene-3-carbonitriles

Derong Ding and Cong-Gui Zhao*

Department of Chemistry, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249-0698

Abstract

2-Amino-8-oxo-tetrahydro-4*H*-chromene-3-carbonitriles were synthesized for the first time from a tandem Michael addition - cyclization reaction between cyclohexane-1,2-dione and benzylidenemalononitriles. An enantioselective synthesis of these compounds was achieved in moderate ee values (up to 63% ee) by using a cinchona alkaloid-derived thiourea catalyst.

Keywords

chromene; tandem reaction; enantioselective; cinchona alkaloid; organocatalysis; 1; 2-cyclohexanedione; benzylidenemalononitrile

Polysubstituted 2-amino-4*H*-pyran-3-carbonitrile derivatives are very important heterocyclic compounds, which frequently exhibit a variety of biological activities.^{1,2} Among these compounds, 2-amino-4*H*-chromene-3-carbonitrile derivatives have been reported to possess anticancer, anticoagulant, and fungicidal activities.² These compounds also find applications as pigments and as potential biodegradable agrochemicals.³ Due to their usefulness, the synthesis of these compounds has attracted a lot of interest.⁴ Most recently, asymmetric syntheses of some of these 2-amino-4*H*-pyran-3-carbonitrile derivatives have also been reported.⁵ Furthermore, the synthesis of partially saturated 2-amino-4*H*-chromene-3-carbonitrile derivatives has also been reported.⁶ For example, the cyclization reaction between 1,3-dicarbonyl compounds and benzylidenemalononitriles in the presence of a suitable base gives 2-amino-5-oxo-5,6,7,8-tetrahydro-4*H*-chromene-3-carbonitriles,⁶ which have also been demonstrated to have biological activities.^{6a} Nonetheless, the synthesis of their 8-oxo analogues has not been reported, although such compounds reportedly are able to alter the lifespan of eukaryotic organisms.⁷

On the other hand, 1,2-diones are highly reactive compounds and have found many applications in organic synthesis.⁸ Nevertheless, they have been seldom used in organocatalyzed reactions.⁹ These few examples are collected below: Göbel and coworkers utilize the dione as an ene-activator in an organocatalyzed Diels-Alder reaction.^{9a} Nair and coworkers reported a lactonization reaction between 1,2-diones and α,β -unsaturated aldehydes catalyzed by an *N*-heterocyclic carbene.^{9b} In 2006, we reported direct cross aldol reaction of 1,2-diones and

* Corresponding author. Tel.: +1-210-458-5432; fax: +1-210-458-7428; cong.zhao@utsa.edu.

Supplementary data: Supplementary data associated with this article can be found, in the online version, at

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ketones catalyzed by proline derivatives.^{9c} Most recently, Rueping and coworkers reported a tandem^{5,10} Michael-aldol reaction of cyclohexane-1,2-dione and α,β -unsaturated aldehydes.^{9d}

We are interested in developing novel enantioselective methods for the synthesis of 2-amino-4*H*-pyran-3-carbonitrile derivatives. In this regard, we developed the first enantioselective synthesis of 6-amino-5-cyanodihydropyrano[2,3-*c*]pyrazoles through a tandem Michael addition-cyclization reaction between 2-pyrazolin-5-ones and benzylidenemalononitriles.^{5b} The fact that cyclohexane-1,2-dione may be enolized and used in a Michael addition reaction under organocatalysis^{9d} prompted us to use of this compound as a potential Michael donor in a tandem Michael addition-cyclization reaction with benzylidenemalononitriles. Herein we wish to report the first general and enantioselective synthesis of 2-amino-8-oxo-5,6,7,8-tetrahydro-4*H*-chromene-3-carbonitriles on the basis of a tandem Michael addition-cyclization reaction between benzylidenemalononitriles and cyclohexane-1,2-dione.

Cyclohexane-1,2-dione (**1**) and benzylidenemalononitrile (**2a**) were adopted as the starting materials for the proposed Michael addition reaction. On the basis of Rueping's results, the reaction of was studied with several readily available organic and inorganic bases as the catalysts. The results are summarized in Table 1.

As shown in Table 1, when the reaction was carried out with 10 mol % DABCO as the base catalyst in toluene at room temperature for 27 h (entry 1), a product, which was identified to be **3a**, was isolated in 75% yield. Unlike Rueping's results,^{9d} no formation of bicyclic products was observed.¹¹ Formation of **3a** may be rationalized by the tandem enolization-Michael addition-enolization-cyclization reaction-tautomerization sequence as shown in Scheme 1. DBU, Et₃N, and K₂CO₃ also catalyze this reaction (entries 2-4), albeit in lower efficiency. However, weaker base NaHCO₃ cannot catalyze the reaction, as no product could be obtained (entry 5). Further screening of the reaction solvents identified that toluene (entry 1), CH₂Cl₂ (entry 6), and THF (entry 7) are good solvents for this reaction, while EtOAc, acetone, and EtOH (entries 8-10) are worse ones. Under the optimized conditions, several substituted benzylidenemalononitriles were applied as the substrate. As shown by the results in Table 1, acceptable to good yields (45-73%) were obtained with benzylidenemalononitriles with an electron-withdrawing group substituent at the *para* position (entries 11-14). Benzylidenemalononitriles with a *meta* substituent (entry 15) or an electron-donating group (entry 16) also led to good results. Heterocyclic thiophen-2-ylmethylidenemalononitrile gave the highest yield of 79% of the desired product (entry 17). Alkylidenemalononitrile **2i** also reacted to produce the expected product **3i**, although the yield is lower and the reaction is sluggish (entry 18). However, other 1,2-diones, such as butane-2,3-dione and 3-methylcyclopentane-1,2-dione, do not yield the expected product (data not shown), with the former gives no product at all and the latter some unidentified products.

Since one stereogenic center is created at the 4-position of product **3** during this reaction, it was our intention to develop an asymmetric version of this reaction by using chiral Lewis base organocatalysts. Thus, with **1** and **2a** as the model substrates, several readily available chiral Lewis base organocatalysts (Figure 1) were screened. The results of this screening are collected in Table 2. As detailed in Table 2, out of the ten catalyst screened, only the quinine-derived thiourea catalysts **4a**, **4b**, and **4c** are giving slightly higher ee values (about 35% ee) when they were applied in toluene at room temperature (entries 1-3), while the rest all generate ee values no greater than 30% (entries 4-10). It should be pointed out that catalysts **4d**, **4e**, **4f**, **4g**, and **4j** (entries 4-7, and 10) produce the other enantiomer as the major product as compared to the rest catalysts. Because catalyst **4a** yields the best yields and the highest ee values among the three best catalysts, further optimizations were focused on catalyst **4a**. Screening different

organic solvents revealed that most of these solvents (entries 11-16) produce worst ee values of the product than toluene does (entry 1). Only in ethanol a higher ee value of 40% was achieved (entry 17). Nevertheless, the attempt to further increase the ee value through lowering the reaction temperature failed in this solvent, since at 0 °C the same ee value was obtained (entry 18). We then went back to toluene and tried to increase the ee value by employing the temperature effects. To our pleasure, with toluene, the ee value of the product **3a** may be increased to 63% at 0 °C (entry 19). However, further dropping of the temperature (to -15 °C) proves to have detrimental effects on both the reactivity and the enantioselectivity of this reaction (entry 20). Once the optimized reaction conditions were found, the other benzylidenemalononitriles were applied to this reaction under these conditions. The results are collected in Table 3.

As shown in Table 3, benzylidenemalononitriles with various substituents all produce the desired product in mediocre to good ee values (43-63% ee, entries 1-7). The yields (49-64%) obtained are usually low because of the formation of some unidentified products in the reaction. The heterocyclic thiophen-2-ylmethylidenemalononitrile also gives the expected product in 47% ee and 37% yield (entry 8). However, the alkylidenemalononitrile **2i** reacts very slowly and leads to poor ee value of the product (entry 9). Again, butane-2,3-dione and 3-methylcyclopentane-1,2-dione failed to yield the desired products (data not shown).

In summary, we have developed the first general synthesis of 2-amino-8-oxo-5,6,7,8-tetrahydro-4*H*-chromene-3-carbonitriles by employing a tandem Michael addition-cyclization reaction between cyclohexane-1,2-dione with benzylidenemalononitriles with DABCO as the catalyst. An enantioselective version of this reaction was also realized (with ee value up to 63%) by using a quinine-derived thiourea catalyst.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research is financially supported by the Welch Foundation (Grant No. AX-1593) and partly by the National Institute of General Medical Sciences (Grant No. 1SC1GM082718-01), for which the authors are most grateful.

References and notes

1. (a) Foloppe N, Fisher LM, Howes R, Potter A, Robertson AGS, Surgenor AE. *Bioorg Med Chem* 2006;14:4792–4802. [PubMed: 16574416] (b) Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. *Proc Natl Acad Sci USA* 2000;97:7124–7129. [PubMed: 10860979] (c) El-Tamany ES, El-Shahed FA, Mohamed BH. *J Serb Chem Soc* 1999;64:9–18. (d) Zaki MEA, Soliman HA, Hiekal OA, Rashad AE. *Z Naturforsch C* 2006;61:1–5. [PubMed: 16610208] (e) Ismail ZH, Aly GM, El-Degwi MS, Heiba HI, Ghorab MM. *Egypt J Biotech* 2003;13:73–82.
2. (a) Konishi K, Kuragano T, Nohara A. *Nippon Noyaku Gakkaishi* 1990;15:241–244. (b) Liao SY, Qian L, Miao TF, Shen Y, Zheng KC. *J Theor Comput Chem* 2009;8:143–155. (c) Kemnitzer W, Jiang S, Wang Y, Kasibhatla S, Crogan-Grundy C, Bubenik M, Labrecque D, Denis R, Lamothe S, Attardo G, Gourdeau H, Tseng B, Drewe J, Cai SX. *Bioorg Med Chem Lett* 2008;18:603–607. [PubMed: 18077161] (d) Kemnitzer W, Drewe J, Jiang S, Zhang H, Crogan-Grundy C, Labrecque D, Bubenick M, Attardo G, Denis R, Lamothe S, Gourdeau H, Tseng B, Kasibhatla S, Cai SX. *J Med Chem* 2008;51:417–423. [PubMed: 18197614] (e) Bonsignore L, Loy G, Secci D, Calignano A. *Eur J Med Chem* 1993;28:517–520. (f) Andreani LL, Lapi E. *Boll Chim Farm* 1960;99:583–586. [PubMed: 13759798]
3. (a) Hafez EAA, Elnagdi MH, Elagamey AGA, Ei-Taweel FMAA. *Heterocycles* 1987;26:903–907. (c) Witte, EC.; Neubert, P.; Roesch, A. *Ger Offen DE3427985*. 1986. *Chem Abstr* 1986;104:224915. (b)

- Morinaka, Y.; Takahashi, K. *Jpn Kokai Tokkyo Koho JP52017498*. 1977. *Chem Abstr* 1977;87:102299.
4. (a) Bloxham J, Dell CP, Smith CW. *Heterocycles* 1994;38:399–408. (b) Elagamey AGA, Sawllim SZ, El-Taweel FMA, Elnagdi MH. *Collect Czech Chem Commun* 1988;53:1534–1538. (c) Ballini R, Bosica G, Conforti ML, Maggi R, Mazzacani A, Righi P, Sartori G. *Tetrahedron* 2001;57:1395–1398. (d) Jin TS, Zhang JS, Liu LB, Wang AQ, Li TS. *Synth Commun* 2006;36:2009–2015. (e) Zhang AQ, Zhang M, Chen HH, Chen J, Chen HY. *Synth Commun* 2007;37:231–235.
5. (a) Wang XS, Yang GS, Zhao G. *Tetrahedron: Asymmetry* 2008;19:709–714. (b) Gogi S, Zhao CG. *Tetrahedron Lett* 2009;52:2252–2255.
6. (a) Kumar D, Reddy VB, Sharad S, Dube U, Kapur S. *Eur J Med Chem* 2009;44:3805–3809. [PubMed: 19419801] (b) Wang XS, Wu JR, Li Q, Tu SJ. *J Chem Res* 2009:234–236. (b) Harb AFA, Hesien AHM, Metwally SA, Elnagdi MH. *Liebigs Ann Chem* 1989:585–588. (c) Martin N, Pascual C, Seoane C, Soto JL. *Heterocycles* 1987;26:2811–2816. (d) Zayed SE, Abou Elmaged EI, Metwally SA, Elnagdi MH. *Collect Czech Chem Commun* 1991;56:2175–2182. (e) Elnagdi MH, Abdel-Motaleb RM, Mustafa M, Zayed MF, Kamel EM. *J Heterocycl Chem* 1987;24:1677–1681.
7. Goldfarb, DS. U.S. Patent US 2009163545. 2009.
8. For selected examples, see: (a) Svennebring A, Nilsson P, Larhed M. *J Org Chem* 2007;72:5851–5854. [PubMed: 17602595] (b) Held I, Xu S, Zipse H. *Synthesis* 2007:1185–1196. (c) Wu S, Fluxe A, Janusz JM, Sheffer JB, Browning G, Blass B, Coburn K, Hedges R, Murawsky M, Fang B, Fadaye GM, Hare M, Djandjighian L. *Bioorg Med Chem Lett* 2006;16:5859–5863. [PubMed: 16942874] (d) Ding Y, Girardet J, Smith KL, Larson G, Prigaro B, Lai VCH, Zhong W, Wu JZ. *Bioorg Med Chem Lett* 2005;15:675–678. [PubMed: 15664835] (e) Curiel D, Cowley A, Beer PD. *Chem Commun* 2005:236–238. (f) Zhao Z, Wisnoski DD, Wolkenberg SE, Leister WH, Wang Y, Lindsley CW. *Tetrahedron Lett* 2004;45:4873–4876. (g) Lindsley CW, Wisnoski DD, Wang Y, Leister WH, Zhao Z. *Tetrahedron Lett* 2003;44:4495–4498. (h) Maruoka H, Kashige N, Miake F, Yamaguchi T. *Chem Pharm Bull* 2005;53:1359–1361. [PubMed: 16205004] (i) Trost BM, Schroeder GM. *J Am Chem Soc* 2000;122:3785–3786.
9. For examples, see, (a) Schuster T, Bauch M, Duerner G, Göbel MW. *Org Lett* 2000;2:179–181. [PubMed: 10814276] (b) Nair V, Vellalath S, Poonoth M, Mohan R, Suresh E. *Org Lett* 2006;8:507–509. [PubMed: 16435871] (c) Samanta S, Zhao CG. *Tetrahedron Lett* 2006;47:3383–3386. (d) Rueping M, Kuenkel A, Tato F, Bats JW. *Angew Chem Int Ed* 2009;48:3699–3702.
10. For some leading examples of chincona alkaloid-catalyzed tandem reactions, see: (a) Tan B, Chua PJ, Li Y, Zhong G. *Org Lett* 2008;10:2437–2440. [PubMed: 18489178] (b) Biddle MM, Lin M, Scheidt KA. *J Am Chem Soc* 2007;129:3830–3831. [PubMed: 17348659] (c) Zu LS, Wang J, Li H, Xie HX, Jiang W, Wang W. *J Am Chem Soc* 2007;129:1036–1037. [PubMed: 17263377] (d) Wang B, Wu F, Wang Y, Liu X, Deng L. *J Am Chem Soc* 2007;129:768–769. [PubMed: 17243806] (e) Wang Y, Liu XF, Deng L. *J Am Chem Soc* 2006;128:3928–3930. [PubMed: 16551098] (f) Dudding T, Hafez AM, Taggi AE, Wagerle TR, Lectka T. *Org Lett* 2002;4:387–390. [PubMed: 11820886] (g) Tan B, Chua PJ, Zeng X, Lu M, Zhong G. *Org Lett* 2008;10:3489–3492. [PubMed: 18630924] (h) Tan B, Shi Z, Chua PJ, Zhong G. *Org Lett* 2008;10:3425–3428. [PubMed: 18616339] For an excellent review on organocatalyzed tandem reactions, see: Enders D, Grondal C, Hüttl MRM. *Angew Chem Int Ed* 2007;46:1570–1581.
11. The reaction does produces some unidentified products, which lowers the yield of the reaction.

Figure 1.
Chiral catalyst screened for the enantioselective synthesis of **3a**

Scheme 1.
Proposed mechanism for the formation of product **3**

Table 1

Tandem Michael addition-cyclization reaction between 1,2-cyclohexanedione (**1**) and benzyldenemalonitriles (**2**)^a

entry	R	2/3	solvent	catalyst	time (h)	yield (%) ^b
1	Ph	a	toluene	DABCO	27	75
2	Ph	a	toluene	DBU	30	43
3	Ph	a	toluene	Et ₃ N	38	67
4	Ph	a	toluene	K ₂ CO ₃	48	29
5	Ph	a	toluene	NaHCO ₃	72	0
6	Ph	a	CH ₂ Cl ₂	DABCO	24	71
7	Ph	a	THF	DABCO	28	74
8	Ph	a	EtOAc	DABCO	27	64
9	Ph	a	acetone	DABCO	29	51
10	Ph	a	EtOH	DABCO	30	61
11	4-ClC ₆ H ₄	b	toluene	DABCO	24	73
12	4-BrC ₆ H ₄	c	toluene	DABCO	30	59
13	4-CNC ₆ H ₄	d	toluene	DABCO	23	45
14	4-NO ₂ C ₆ H ₄	e	toluene	DABCO	22	64
15	3-BrC ₆ H ₄	f	toluene	DABCO	20	65
16	4-CH ₃ C ₆ H ₄	g	toluene	DABCO	25	67
17	thiophen-2-yl	h	toluene	DABCO	26	79
18	CH ₃ (CH ₂) ₅	i	toluene	DABCO	32	39

^a All reactions were conducted with the indicated arylidenemalonitrile (**2**, 0.30 mmol), 1,2-cyclohexanedione (**1**, 0.32 mmol), and the catalyst (10 mmol %, 0.03 mmol) in the specified solvent (1.5 mL) at room temperature.

^bYield of isolated product after column chromatography.

Table 2

Catalst screening for the enantioselective synthesis of **3a**^a

entry	solvent	catalyst	time (h)	yield (%) ^b	ee (%) ^c
1	toluene	4a	26	56	35
2	toluene	4b	30	41	35
3	toluene	4c	30	47	34
4	toluene	4d	28	37	30 ^d
5	toluene	4e	240	21	1 ^d
6	toluene	4f	40	34	27 ^d
7	toluene	4g	26	70	25 ^d
8	toluene	4h	168	31	3
9	toluene	4i	28	61	16
10	toluene	4j	28	72	3 ^d
11	CH ₂ Cl ₂	4a	30	43	18
12	Et ₂ O	4a	28	55	17
13	EtOAc	4a	28	35	25
14	THF	4a	40	33	33
15	CHCl ₃	4a	38	33	6

entry	solvent	catalyst	time (h)	yield (%) ^b	ee (%) ^c
16	CH ₃ CN	4a	28	31	15
17	EtOH	4a	28	53	40
18 ^e	EtOH	4a	72	58	40
19 ^e	toluene	4a	28	64	63
20 ^f	toluene	4a	28	43	59

^a Unless otherwise indicated, all reactions were conducted with benzylidenemalononitrile **2a** (0.30 mmol), cyclohexane-1,2-dione (0.32 mmol), and the catalyst (10 mmol %, 0.030 mmol) in the specified solvent (1.5 mL) at room temperature.

^b Yield of isolated product after column chromatography.

^c Determined by HPLC analysis on a ChiralCel OD-H column.

^d The opposite enantiomer was obtained as the major product in these cases.

^e The reaction was conducted at 0 °C.

^f The reaction was conducted at -15 °C.

Table 3

Enantioselective synthesis of 2-amino-8-oxo-tetrahydro-4*H*-chromene-3-carbonitriles^a

entry	R	3	time (h)	yield (%) ^b	ee (%) ^c
1	Ph	3a	28	64	63
2	4-ClC ₆ H ₄	3b	24	60	58
3	4-BrC ₆ H ₄	3c	30	55	57
4	4-CN C ₆ H ₄	3d	24	51	43
5	4-NO ₂ C ₆ H ₄	3e	26	55	48
6	3-BrC ₆ H ₄	3f	24	63	52 ^d
7	4-CH ₃ C ₆ H ₄	3g	28	49	50
8	thiophen-2-yl	3h	30	37	47 ^e
9	CH ₃ (CH ₂) ₅	3i	96	12	9 ^d

^a All reactions were conducted with the benzyldienemalononitrile (0.30 mmol), cyclohexane-1,2-dione (0.32 mmol), and catalyst **4a** (10 mol %, 0.030 mmol) in toluene (1.5 mL) at 0 °C.

^b Yield of isolated product after column chromatography.

^c Unless otherwise specified, ee values were determined by HPLC analysis on a ChiralCel OD-H column.

^d Determined by HPLC analysis on a ChiralPak AD-H column.

^e Determined by HPLC analysis on a ChiralPak AS column.